Inhibition of specific adenylyl cyclase isoforms by lithium and carbamazepine, but not valproate, may be related to their antidepressant effect

Bipolar Disorders

Volumn 11, Issue 8, 2009, Pages 885-896

  Mann, Liad ^a,b   Heldman, Eliahu ^a   Bersudsky, Yuly ^b,c   Vatner, Stephen F ^d   Ishikawa, Yoshihiro ^d,e   Almog, Orna ^a   Belmaker, Robert H ^b,c   Agam, Galila ^a,b  

^a Department of Clinical Biochemistry ^*  (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c MENTAL HEALTH CENTER   (Israel)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenylyl cyclase; Carbamazepine; Lithium; Mood stabilization; Valproate

Indexed keywords

ADENYLATE CYCLASE; AMPHETAMINE; CARBAMAZEPINE; CYCLIC AMP; DOPAMINE 1 RECEPTOR; FORSKOLIN; LITHIUM; MAGNESIUM ION; VALPROIC ACID;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CELL FRACTIONATION; COMPUTER MODEL; CONTROLLED STUDY; DEPRESSION; DOPAMINE RECEPTOR BLOCKING; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; DRUG TARGETING; ENZYME INHIBITION; FEMALE; FORCED SWIMMING TEST; GENETIC TRANSFECTION; HYPERACTIVITY; KNOCKOUT MOUSE; MALE; MANIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ADENYLATE CYCLASE; AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIMANIC AGENTS; BENZAZEPINES; CARBAMAZEPINE; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLIC AMP; DOPAMINE AGONISTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FORSKOLIN; GENE EXPRESSION REGULATION; ISOENZYMES; LITHIUM; MICE; MICE, KNOCKOUT; MODELS, MOLECULAR; MOTOR ACTIVITY; ROTAROD PERFORMANCE TEST; SWIMMING; TRANSFECTION; VALPROIC ACID;

EID: 71049139007     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2009.00762.x     Document Type: Article

References (85)

1. Dousa T, Hechter O. Lithium and brain adenyl cyclase. Lancet 1970, 1:834-835.
2. Ebstein R, Belmaker R, Grunhaus L, Rimon R. Lithium inhibition of adrenaline-stimulated adenylate cyclase in humans. Nature 1976, 259:411-413.
3. Ebstein RP, Hermoni M, Belmaker RH. The effect of lithium on noradrenaline-induced cyclic AMP accumulation in rat brain: inhibition after chronic treatment and absence of supersensitivity. J Pharmacol Exp Ther 1980, 213:161-167.
4. Mork A, Geisler A. The effects of lithium in vitro and ex vivo on adenylate cyclase in brain are exerted by distinct mechanisms. Neuropharmacology 1989, 28:307-311.
5. Newman ME, Belmaker RH. Effects of lithium in vitro and ex vivo on components of the adenylate cyclase system in membranes from the cerebral cortex of the rat. Neuropharmacology 1987, 26:211-217.
6. Palmer GC, Jones DJ, Medina MA, Stavinoha WB. Anticonvulsant drug actions on in vitro and in vivo levels of cyclic AMP in the mouse brain. Epilepsia 1979, 20:95-104.
7. Myllyla VV. Effect of convulsions and anticonvulsive drugs on cerebrospinal fluid cyclic AMP in rabbits. Eur Neurol 1976, 14:97-107.
8. Chen G, Pan B, Hawver DB, Wright CB, Potter WZ, Manji HK. Attenuation of cyclic AMP production by carbamazepine. J Neurochem 1996, 67:2079-2086.
9. Elphick M, Taghavi Z, Powell T, Godfrey PP. Chronic carbamazepine down-regulates adenosine A2 receptors: studies with the putative selective adenosine antagonists PD115,199 and PD116,948. Psychopharmacology 1990, 100:522-529.
10. Ferrendelli JA, Kinscherf DA. Inhibitory effects of anticonvulsant drugs on cyclic nucleotide accumulation in brain. Ann Neurol 1979, 5:533-538.
11. Chen G, Manji HK, Wright CB, Hawver DB, Potter WZ. Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. Neuropsychopharmacology 1996, 15:271-280.
12. Post RM, Ballenger JC, Uhde TW, Smith C, Rubinow DR, Bunney WE. Effect of carbamazepine on cyclic nucleotides in CSF of patients with affective illness. Biol Psychiatry 1982, 17:1037-1045.
13. Gallagher HC, Bacon CL, Odumeru OA, Gallagher KF, Fitzpatrick T, Regan CM. Valproate activates phosphodiesterase-mediated cAMP degradation: relevance to C6 glioma G1 phase progression. Neurotoxicol Teratol 2004, 26:73-81.
14. Montezinho LP, Mork A, Duarte CB, Penschuck S, Geraldes CF, Castro MM. Effects of mood stabilizers on the inhibition of adenylate cyclase via dopamine D(2)-like receptors. Bipolar Disord 2007, 9:290-297.
15. Montezinho LP, Castro MM, Duarte CB, Penschuck S, Geraldes CF, Mork A. The interaction between dopamine D2-like and beta-adrenergic receptors in the prefrontal cortex is altered by mood-stabilizing agents. J Neurochem 2006, 96:1336-1348.
16. Mann L, Heldman E, Shaltiel G, Belmaker RH, Agam G. Lithium preferentially inhibits adenylyl cyclase V and VII isoforms. Int J Neuropsychopharmacol 2008, 11:533-539.
17. Hanoune J, Defer N. Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 2001, 41:145-174.
18. Cooper DM. Regulation and organization of adenylyl cyclases and cAMP. Biochem J 2003, 375:517-529.
19. Defer N, Marinx O, Stengel D. Molecular cloning of the human type VIII adenylyl cyclase. FEBS Lett 1994, 351:109-113.
20. Hurley JH. The adenylyl and guanylyl cyclase superfamily. Curr Opin Struct Biol 1998, 8:770-777.
21. Krupinski J. The adenylyl cyclase family. Mol Cell Biochem 1991, 104:73-79.
22. Mons N, Harry A, Dubourg P, Premont RT, Iyengar R, Cooper DM. Immunohistochemical localization of adenylyl cyclase in rat brain indicates a highly selective concentration at synapses. Proc Natl Acad Sci USA 1995, 92:8473-8477.
23. Sunahara RK, Taussig R. Isoforms of mammalian adenylyl cyclase: multiplicities of signaling. Mol Interv 2002, 2:168-184.
24. Srinivasan C, Toon J, Amari L. Competition between lithium and magnesium ions for the G-protein transducin in the guanosine 5′-diphosphate bound conformation. J Inorg Biochem 2004, 98:691-701.
25. Ebstein RP, Moscovich D, Zeevi S, Amiri Z, Lerer B. Effect of lithium in vitro and after chronic treatment on human platelet adenylate cyclase activity: postreceptor modification of second messenger signal amplification. Psychiatry Res 1987, 21:221-228.
26. Mork A, Geisler A. Mode of action of lithium on the catalytic unit of adenylate cyclase from rat brain. Pharmacol Toxicol 1987, 60:241-248.
27. Mork A, Geisler A. Effects of lithium on calmodulin-stimulated adenylate cyclase activity in cortical membranes from rat brain. Pharmacol Toxicol 1987, 60:17-23.
28. Avissar S, Murphy DL, Schreiber G. Magnesium reversal of lithium inhibition of beta-adrenergic and muscarinic receptor coupling to G proteins. Biochem Pharmacol 1991, 41:171-175.
29. Iwamoto T, Iwatsubo K, Okumura S. Disruption of type 5 adenylyl cyclase negates the developmental increase in Galphaolf expression in the striatum. FEBS Lett 2004, 564:153-156.
30. Lee KW, Hong JH, Choi IY. Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase. J Neurosci 2002, 22:7931-7940.
31. Kim KS, Han PL. Mice lacking adenylyl cyclase-5 cope badly with repeated restraint stress. J Neurosci Res 2009, 87:2983-2993.
32. Kim KS, Kim J, Back SK, Im JY, Na HS, Han PL. Markedly attenuated acute and chronic pain responses in mice lacking adenylyl cyclase-5. Genes Brain Behav 2007, 6:120-127.
33. Kim KS, Lee KW, Baek IS. Adenylyl cyclase-5 activity in the nucleus accumbens regulates anxiety-related behavior. J Neurochem 2008, 107:105-115.
34. Krishnan V, Graham A, Mazei-Robison MS. Calcium-sensitive adenylyl cyclases in depression and anxiety: behavioral and biochemical consequences of isoform targeting. Biol Psychiatry 2008, 64:336-343.
35. Yan L, Vatner DE, O'Connor JP. Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell 2007, 130:247-258.
36. Okumura S, Kawabe J, Yatani A. Type 5 adenylyl cyclase disruption alters not only sympathetic but also parasympathetic and calcium-mediated cardiac regulation. Circ Res 2003, 93:364-371.
37. Okumura S, Takagi G, Kawabe J. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci U S A 2003, 100:9986-9990.
38. Nevo I, Avidor-Reiss T, Levy R, Bayewitch M, Heldman E, Vogel Z. Regulation of adenylyl cyclase isozymes on acute and chronic activation of inhibitory receptors. Mol Pharmacol 1998, 54:419-426.
39. Avidor-Reiss T, Nevo I, Saya D, Bayewitch M, Vogel Z. Opiate-induced adenylyl cyclase superactivation is isozyme-specific. J Biol Chem 1997, 272:5040-5047.
40. Avidor-Reiss T, Nevo I, Levy R, Pfeuffer T, Vogel Z. Chronic opioid treatment induces adenylyl cyclase V superactivation. Involvement of Gbetagamma. J Biol Chem 1996, 271:21309-21315.
41. Salomon Y. Cellular responsiveness to hormones and neurotransmitters: conversion of [3H]adenine to [3H]cAMP in cell monolayers, cell suspensions, and tissue slices. Methods Enzymol 1991, 195:22-28.
42. Iwamoto T, Okumura S, Iwatsubo K. Motor dysfunction in type 5 adenylyl cyclase-null mice. J Biol Chem 2003, 278:16936-16940.
43. Porsolt RD, Brossard G, Hautbois C, Roux S. Rodent models of depression: forced swimming and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci 2001, (Suppl. 14):Unit 8.10A. Chapter 8
44. Banger M, Hiemke C, Knuppen R, Ball P, Haupt M, Wiedemann K. Formation and metabolism of catecholestrogens in depressed patients. Biol Psychiatry 1990, 28:685-696.
45. Paul SM, Axelrod J. Catechol estrogens: presence in brain and endocrine tissues. Science 1977, 197:657-659.
46. Steegborn C, Litvin TN, Hess KC. A novel mechanism for adenylyl cyclase inhibition from the crystal structure of its complex with catechol estrogen. J Biol Chem 2005, 280:31754-31759.
47. Steegborn C, Litvin TN, Levin LR, Buck J, Wu H. Bicarbonate activation of adenylyl cyclase via promotion of catalytic active site closure and metal recruitment. Nat Struct Mol Biol 2005, 12:32-37.
48. Lieb K, Treffurth Y, Hamke M, Akundi RS, von Kleinsorgen M, Fiebich BL. Valproic acid inhibits substance P-induced activation of protein kinase C epsilon and expression of the substance P receptor. J Neurochem 2003, 86:69-76.
49. Gille A, Lushington GH, Mou TC, Doughty MB, Johnson RA, Seifert R. Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides. J Biol Chem 2004, 279:19955-19969.
50. Malarkey CS, Wang G, Ballicora MA, Mota de Freitas DE. Evidence for two distinct Mg2+ binding sites in G(s alpha) and G(i alpha1) proteins. Biochem Biophys Res Commun 2008, 372:866-869.
51. Van Calker D, Steber R, Klotz KN, Greil W. Carbamazepine distinguishes between adenosine receptors that mediate different second messenger responses. Eur J Pharmacol 1991, 206:285-290.
52. Biber K, Fiebich BL, Gebicke-Harter P, van Calker D. Carbamazepine-induced upregulation of adenosine A1-receptors in astrocyte cultures affects coupling to the phosphoinositol signaling pathway. Neuropsychopharmacology 1999, 20:271-278.
53. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990, 42:223-286.
54. Hurley JH. Structure, mechanism, and regulation of mammalian adenylyl cyclase. J Biol Chem 1999, 274:7599-7602.
55. Iwatsubo K, Minamisawa S, Tsunematsu T. Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration. J Biol Chem 2004, 279:40938-40945.
56. Onda T, Hashimoto Y, Nagai M. Type-specific regulation of adenylyl cyclase. Selective pharmacological stimulation and inhibition of adenylyl cyclase isoforms. J Biol Chem 2001, 276:47785-47793.
57. Wrinch D. A contemporary picture of the chemical aspects of polypeptide chain structures and certain problems of molecular biology. Nature 1965, 206:459-461.
58. Teepker M, Anthes N, Krieg JC, Vedder H. 2-OH-estradiol, an endogenous hormone with neuroprotective functions. J Psychiatr Res 2003, 37:517-523.
59. Chuang DM. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases?. Crit Rev Neurobiol 2004, 16:83-90.
60. O'Brien WT, Harper AD, Jove F. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004, 24:6791-6798.
61. Bersudsky Y, Shaldubina A, Belmaker RH. Lithium's effect in forced-swim test is blood level dependent but not dependent on weight loss. Behav Pharmacol 2007, 18:77-80.
62. Dilsaver SC, Benazzi F, Akiskal KK, Akiskal HS. Differential patterns of lifetime multiple anxiety disorder comorbidity between Latino adults with bipolar I and major depressive disorders. Bull Menninger Clin 2008, 72:130-148.
63. Salvatore P, Tohen M, Khalsa HM, Baethge C, Tondo L, Baldessarini RJ. Longitudinal research on bipolar disorders. Epidemiol Psichiatr Soc 2007, 16:109-117.
64. Kim KS, Lee KW, Lee KW. Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine action. Proc Natl Acad Sci U S A 2006, 103:3908-3913.
65. Ogden CA, Rich ME, Schork NJ. Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach. Mol Psychiatry 2004, 9:1007-1029.
66. Gould TD, O'Donnell KC, Picchini AM, Manji HK. Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology 2007, 32:1321-1333.
67. Einat H, Manji HK, Belmaker RH. New approaches to modeling bipolar disorder. Psychopharmacol Bull 2003, 37:47-63.
68. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev 1998, 78:189-225.
69. Maj J, Dziedzicka-Wasylewska M, Rogoz R, Rogoz Z, Skuza G. Antidepressant drugs given repeatedly change the binding of the dopamine D2 receptor agonist, [3H]N-0437, to dopamine D2 receptors in the rat brain. Eur J Pharmacol 1996, 304:49-54.
70. Maj J, Dziedzicka-Wasylewska M, Rogoz R, Rogoz Z. Effect of antidepressant drugs administered repeatedly on the dopamine D3 receptors in the rat brain. Eur J Pharmacol 1998, 351:31-37.
71. Gershon AA, Vishne T, Grunhaus L. Dopamine D2-like receptors and the antidepressant response. Biol Psychiatry 2007, 61:145-153.
72. Glatt CE, Snyder SH. Cloning and expression of an adenylyl cyclase localized to the corpus striatum. Nature 1993, 361:536-538.
73. Matsuoka I, Suzuki Y, Defer N, Nakanishi H, Hanoune J. Differential expression of type I, II, and V adenylyl cyclase gene in the postnatal developing rat brain. J Neurochem 1997, 68:498-506.
74. Mons N, Cooper DM. Selective expression of one Ca(2+)-inhibitable adenylyl cyclase in dopaminergically innervated rat brain regions. Brain Res Mol Brain Res 1994, 22:236-244.
75. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004, 161:564-566.
76. Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 2001, 34:137-141.
77. Mann JJ, Brown RP, Halper JP. Reduced sensitivity of lymphocyte beta-adrenergic receptors in patients with endogenous depression and psychomotor agitation. N Engl J Med 1985, 313:715-720.
78. Extein I, Tallman J, Smith CC, Goodwin FK. Changes in lymphocyte beta-adrenergic receptors in depression and mania. Psychiatry Res 1979, 1:191-197.
79. Rahman S, Li PP, Young LT, Kofman O, Kish SJ, Warsh JJ. Reduced [3H]cyclic AMP binding in postmortem brain from subjects with bipolar affective disorder. J Neurochem 1997, 68:297-304.
80. Young LT, Li PP, Kish SJ. Cerebral cortex Gs alpha protein levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder. J Neurochem 1993, 61:890-898.
81. Wright AF, Crichton DN, Loudon JB, Morten JE, Steel CM. Beta-adrenoceptor binding defects in cell lines from families with manic-depressive disorder. Ann Hum Genet 1984, 48:201-214.
82. Ebstein RP, Oppenheim G, Ebstein BS, Amiri Z, Stessman J. The cyclic AMP second messenger system in man: the effects of heredity, hormones, drugs, aluminum, age and disease on signal amplification. Prog Neuropsychopharmacol Biol Psychiatry 1986, 10:323-353.
83. Ebstein RP, Lerer B, Shapira B, Shemesh Z, Moscovich DG, Kindler S. Cyclic AMP second-messenger signal amplification in depression. Br J Psychiatry 1988, 152:665-669.
84. Halper JP, Brown RP, Sweeney JA, Kocsis JH, Peters A, Mann JJ. Blunted beta-adrenergic responsivity of peripheral blood mononuclear cells in endogenous depression. Isoproterenol dose-response studies. Arch Gen Psychiatry 1988, 45:241-244.
85. Healy D, Carney PA, Leonard BE. Monoamine-related markers of depression: changes following treatment. J Psychiatr Res 1982, 17:251-260.